Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls

Laurent Dukas; Erich Schacht; Martin Runge; JohannD. Ringe

doi:10.1055/s-0031-1296321

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2010; 60(8): 519-525
DOI: 10.1055/s-0031-1296321

Anti-osteoporotic Drugs

Editio Cantor Verlag Aulendorf (Germany)

Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls

Laurent Dukas

¹Department of Medicine, Institut für Hausarztmedizin IHAMB, Basel, Switzerland

²Ambulatorium Wiesendamm, Basel, Switzerland

³Department of Medicine, Acute Geriatric University Clinic, Basel, Switzerland

,

Erich Schacht

⁴Zürich Osteoporosis Research Group ZORG, Zollikerberg, Switzerland

,

Martin Runge

⁵Aerpah Clinic Esslingen, Esslingen, Germany

,

JohannD. Ringe

⁶West German Osteoporosis (WOC) and Medical Clinic 4, Klinikum Leverkusen, University of Cologne, Germany

› Author Affiliations

Abstract

Purpose:

In an open observational prospective multicentered study on a cohort of patients with a creatinine clearance of ≤ 65 ml/min and diagnosed with the “Esslinger Fall Risk Assessment” to be at an increased risk for falls the effect of daily treatment with 1 µg alfacalcidol (CAS 41294-56-8; Alpha-D₃) on muscle power, balance and number of fallers and falls was investigated.

Methods:

In this open prospective study on 237 participants recruited in Germany, 16.9% men and 83.1% women with a mean age of 75.9 years and a mean body mass index (BMI) of 26.3 kg/m² underwent at the beginning and after 3 and 6 months different muscle strength and balance tests such as the Timed-up and Go Test (TUG), the Tandem Stand Test (TST) and the Chair Rising Test (CRT). A successful performance in these tests has been associated with a significantly lower risk for falls and non-vertebral fractures in elderly patients (successful test performance: TUG < 12 s, TST > 10 s, CRT < 10 s).

Results:

Controlled for age, gender and BMI, treatment with alfacalcidol was associated with a significantly increased performance in all three muscle and balance tests already after 3 months. This effect increased after six months of therapy and a significant increase in the number of participants who were able to successfully perform the different tests was observed: plus 74.9% for the TUG (p < .0001), plus 112% for the TST (p < .0001) and plus 108% for the CRT (p < .0001). After six months the mean time used for the TUG was decreased by 2.01 s, by 2.29 s for the CRT, and increased by 2.02 s for the TST.

Controlled for age, gender, BMI and CrCl, treatment with alfacalcidol for six months resulted in a significant 48.1% (p < .0001) decrease in the absolute number of fallers and a significant 51.3% (p < .0001) decrease in the absolute number of falls, compared to the 6 months prior to alfacalcidol therapy.

Conclusions:

Treatment with alfacalcidol increases muscle power and balance as measured with three different muscle power and balance tests and leads to a highly significant decrease in the number of fallers and falls.

Key words

Alfacalcidol - Balance - CAS 41294-56-8 - Creatinine clearance - Falls and fractures - Muscle power

Full Text

References

References
1 Tinetti ME, Inouye SK, Gill TM, Doucette JT.. Shared risk factors for falls, incontinence, and functional dependence: unifying the approach to geriatric syndromes. JAMA. 1995; 273 (17) 348-53
2 Birge SJ.. Osteoporotic fractures: a brain or bone disease?. Curr Osteoporos Rep. 2008; 6: 57-61
3 Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C.. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J. Bone Miner Res. 2000; 15 (6) 1113-8
4 Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Stae-helin HB, Bazemore MG, Zee RY et al. Effect of vitamin D on falls: a meta analysis. JAMAD. 2004; 291: 1999-2006
5 Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm T et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of 500 mg daily. J Am Geriatr Soc. 2004; 52: 1-7
6 Gallagher JC.. The effects of calcitriol on falls and fractures and physical performance tests. J. Steroid Biochem Mol Biol. 2004; 89 90:497 (501)
7 Richy F, Dukas L, Schacht E.. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008; 82: 102-7
8 Schacht E.. Reduction of falls and osteoporotic fractures: plain vitamin D or D-hormone analogs?. Geriatr Gerontol Int. 2008; 8 (01) S16-S25
9 Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshi-zawa T et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology. 2003; 144 (12) 5138-44
10 Boland R.. Role of vitamin D in skeletal muscle function. Endocr Rev. 1986; 7: 434-47
11 Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-8
12 Dukas LC, Schacht E, Mazor Z, Stahelin HB.. A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int. 2005; 16 (3) 332-8
13 Dukas L, Schacht E, Stahelin HB.. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int. 2005; 16 (12) 1683-90
14 Gallagher JC, Rapuri PB, Smith LM.. An age related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol. J Clin Endocrinol Metab. 2007; 92: 51-8
15 Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL et al. Study of osteoporotic fractures research group, renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007; 167: 133-9
16 Dukas LC, Runge M, Schacht E.. Significant lower balance and muscle power performance and higher risk of falls in elderly people with a decreasing creatinine clearance. Osteoporos Int. 2008; 19 (01) S127 (8)
17 Dukas L, Schacht E, Runge M.. Independent from muscle power and balance performance a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis. Osteoporos Int. 2010; 21: 1237-45
18 Runge M, Schacht E.. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J. Musculoskelet Neuronal Interact. 2005; 5 (2) 127-34
19 German Guidelines 2005: DVO-Leitlinie – Osteoporose bei postmenopausalen Frauen [ www.dv-osteologie.org/dvoletilinien ] 2003 (serial online); (46 screens). Available from: http://www.lutherhaus.de/osteo/leitlinien-dvo/
20 German Guidelines 2009: DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen [ www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie ] Available from: http://www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie-2009 Langfassung Version 06-03-09.pdf
21 Cockcroft DW, Gault MH.. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1) 31-41
22 Podsialdo D, Richardson S.. The timed “up&go”: a test of basic functional mobility for frail elderly persons. J. Am Geriatr Soc. 1991; 39 (2) 142-8
23 Mathias S, Nayak US, Isaacs B.. Balance in elderly patients: the “get-up and go” test. Arch Phys Med Rehabil. 1986; 67 (6) 387-9
24 Zhu K, Devine A, Prince RL.. Timed up and go test and BMD as predictors of fractures: a 10 year longitudinal study. Bone Min Res. 2008; 23-sll9
25 Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB.. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Eng J Med. 1995; 332: 556-61
26 Gill TM, Williams CS, Tinetti ME.. Assessing risk for the onset of functional dependence among older adults: the role of physical performance. J Am Geriatr Soc. 1995; 43: 603-9
27 Winer BJ. Statistical principles in experimental design. 2nd ed New York: McGraw Hill; 1971: 514
28 Danneskiold-Samsoe B, Kofod V, Munter J.. Muscle strength and functional capacity in 78–81 year old men and women. Eur J Appl Physiol. 1984; 52: 310-4
29 Tinetti ME, Williams CS.. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci. 1998; 53 (2) M112-9
30 Richy F, Deroisy R, Lecart MP, Hanssens L, Mawet A, Re-ginster JY.. D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res. 2005; 17: 133-42
31 Schacht E, Richy F, Reginster JY.. The therapeutic effects of Alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005; 5: 273-84
32 Dukas L, Schacht E, Mazor Z, Staehelin HB.. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 65 ml/min. Osteoporos Int. 2005; 16: 198-203
33 Bischoff HA, Staehelin HB, Urscheler N, Ehrsam R, Vonthein R, Perrig-Chiello P et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil. 1999; 80: 54-8
34 Dukas L, Staehelin HB, Schacht E, Bischoff HA.. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and a to a daily calcium intake. Nutr Health Aging. 2005; 9 (5) 347-51
35 Sorensen OH, Lund BI, Saltin B, Lund BJ, Anderson RB, Hyorth L et al. Myopathy in bone loss of aging: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci. 1979; 56: 157-61
36 Verhaar HJJ, Samson MM, Jansen PAF, deVreede PL, Manten JW, Dursma SA.. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000; 12: 455-60
37 Scharia SH, Schacht E, Lempert UG, Alfacalcidol PL. versus plain vitamin D in inflammation induced bone loss. J Rheumatol. 2005; Sep 76: 26-32
38 Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa Y, Kamo K, Shimada Y. Effects of Alfacalcidol on Bone and Skeletal Musclein Glucocorticoid treated Rats. J Bone Miner Res. 2008; 23: 427
39 Koike T, Okawa T, Wada M, Kita T, Takaoka K.. Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Miner Res. 2003; 18 ((S2)) S168
40 Schacht E, Richy F.. Reduction of falls in elderly. The central role of alfacalcidol in a multi-dimensional paradigm. Internet J Epidemiol. 2009; 7 (1)
41 Ringe JD, Schacht E.. Potential of alfacalcidol for reducing increased risk of falls and fractures. Rheumatol Int. 2009; 29: 1177
42 Jassal SK, vonMuhlen D, Barrett-Connor E.. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo Study. J Bone Miner Res. 2007; 22: 203-10
43 Dhesi JK, Bearne LM, Monitz C, Hurley MV, Jackson SHD, Swift CG et al. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res. 2002; 17: 891-7
44 Stein MS, Wark JD, Scherer SC, Walton SL, Chick P, DiCar-lantonio M et al. Falls related to vitamin D and parathyroid hormone in Australian nursing home and hostel. J Am GerSoc. 1999; 47: 1195-201
45 Faulkner KA, Cauley JA, Zmuda JM, Landsittel DP, Newman AB, Studenski SA et al. Higher 1, 25-dihydroxyvitamin D3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int. 2006; 17 (9) 1318-28
46 Gryfe CI, Amies A, Ashley MJ.. A longitudinal study of falls in an elderly population: incidence and morbidity. Age Ageing. 1997; 6 (4) 201-10
47 Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE et al. The relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003; 14: 570-76